For the year ending 2025-12-31, ONCO made $815,371 in revenue. -$15,530,937 in net income. Net profit margin of -1904.77%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 815,371 | |||
| Cost of revenue | 182,458 | |||
| Gross profit | 632,913 | |||
| Selling, general and administrative | 7,043,902 | |||
| Research and development | -66,133 | |||
| Impairment of goodwill | 11,512,000 | |||
| Impairment of entadfi assets | 0 | |||
| Impairment of intangibles | 0 | |||
| Total operating expenses | 18,489,769 | |||
| Loss from operations | -17,856,856 | |||
| Loss on extinguishment of note payable | -5,384,719 | |||
| Loss on issuance of preferred stock and warrants | 3,674,329 | |||
| Loss on extinguishment of preferred stock | 196,244 | |||
| Interest expense | 751,005 | |||
| Interest income | 2 | |||
| Change in fair value of subscription agreement liability | 3,127,962 | |||
| Change in fair value of contingent warrant liabilities | -16,499 | |||
| Change in fair value of series d warrant liability | 10,377,638 | |||
| Change in fair value of series d derivative liability | 3,809,333 | |||
| Change in fair value of series e warrant liability | -4,486,847 | |||
| Change in fair value of series e derivative liability | 1,539,014 | |||
| Gain on forgiveness of accounts payable | 944,694 | |||
| Other income | 226,041 | |||
| Interest expense related party | 0 | |||
| Total other income (expense) | 3,825,039 | |||
| Loss before income taxes | -14,031,817 | |||
| Income tax (expense) benefit | 525 | |||
| Net loss | -14,032,342 | |||
| Deemed dividend series c preferred stock | 1,498,595 | |||
| Net loss applicable to common stockholders | -15,530,937 | |||
| Basic EPS | -16.56 | |||
| Diluted EPS | -16.56 | |||
| Basic Average Shares | 937,690 | |||
| Diluted Average Shares | 937,690 | |||
Onconetix, Inc. (ONCO)
Onconetix, Inc. (ONCO)